[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lung-cancer-screening-program\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lung-cancer-screening-program":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100583477","inpatient-capture-a-mixed-methods-study-to-develop-an-inpatient-lung-cancer-screening-program-in-a-safety-net-hospital-100583477",false,"NCT06876831","Inpatient Capture: A Mixed Methods Study to Develop an Inpatient Lung Cancer Screening Program in a Safety Net Hospital.","Inclusion Criteria:\n\n* 50-80 years of age\n* greater than or equal to 20 pack year history\n* currently smoking or have quit within the last 15 years\n\nExclusion Criteria:\n\n* \\\u003C 50 years of age, \\> 80 years of age\n* \\\u003C 20 pack year history\n* quit smoking greater than 15 years",true,"ALL","50 Years","80 Years",{"count":20,"type":21},150,"ESTIMATED","INTERVENTIONAL",[24],"NA","Lung cancer continues to be the leading cause of cancer death in the United States. There are several important disparities in lung cancer mortality: racial and ethnic minorities, those with serious mental illness and those with lower socioeconomic status experience higher lung cancer mortality compared to the general population. Lung cancer screening (LCS) with annual low dose chest CT can reduce lung cancer mortality by 20% for high-risk patients, but has been generally underutilized with uptake of 5-15% by eligible patients across the United States. Half of all patients eligible for LCS remain current smokers, and the additional benefits of tobacco cessation services can increase the benefits of LCS clinical encounters in these patients. Despite the proven benefit of LCS and tobacco cessation, it remains out of reach for many with barriers across the patient, provider, and health-care system levels with resultant disparities in uptake of LCS and effective tobacco cessation that may exaggerate disparities in clinical lung cancer early detection and mortality. The majority of LCS care occurs across several visits in an outpatient clinical setting, which may make it inaccessible to the most vulnerable patients.\n\nOur central objective is to extend the reach of lung cancer and tobacco screening through the implementation and evaluation of a program extending these services inpatient in a public hospital that serves a known high-risk and diverse population in East Harlem. Preliminary data obtained from a retrospective quality improvement project examined data from patients admitted over a 3 month period in early 2022. Of 1374 unique patients were admitted to our hospital, 112 patients met LCS eligibility criteria and over 80% had no evidence of having been screened. Forty-seven percent identified as Black and 33.9% as Hispanic, groups known to have worse lung cancer outcomes. While smoking data was incomplete on a majority of patients, 75% of all inpatient admissions were noted to be currently smoking. This, our preliminary data suggest that an inpatient program to provide smoking cessation and LCS in a safety-net hospital may be an effective tool to increase the reach of LCS in a known high-risk demographic and address disparities in LCS and tobacco cessation services.\n\nThis proposal represents a prospective pilot study to develop, implement and evaluate an inpatient LCS and tobacco cessation program.",[27],"Lung Cancer Screening Program","RECRUITING","2025-03-10",{"date":31,"type":32},"2025-03-14","ACTUAL",{"date":29,"type":21},{"date":35,"type":21},"2025-12-31",{"name":37,"class":38},"Physician Affiliate Group of New York","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":15,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":64,"leadSponsor":66,"locationsCount":39},"100564207","development-of-an-artificial-intelligence-model-for-the-identification-and-prevention-of-smoking-related-diseases-100564207","NCT06626178","Development of an Artificial Intelligence Model for the Identification and Prevention of Smoking-related Diseases.","ARtificial Intelligence for heAlth and Prevention of Smoking-related Diseases","ARIA","High-risk screening subjects\n\nInclusion Criteria:\n\n* Age \\>= 50 years old\n* Active smokers\n* Former smokers (from no more than 15 years)\n* Pack\u002Fyear \\>20\n* Risk-prediction model from Prostate, Lung, Colorectal, and Ovarian study (PLCOm2012) \\>1.2%\n* Provision and signature of informed consent\n\nExclusion Criteria:\n\n* Previous or concurrent neoplastic disease, excluding skin cancers\n* Cognitive or other problems that could hinder the collection of informed consent\n* Severe pulmonary or extra pulmonary disease\n* Previous low-dose computed tomography (CT) scan in the past 12 months\n\nPrevious high-risk positive screening subjects\n\nInclusion Criteria:\n\n* Subjects enrolled in previous lung cancer screening with the presence of lung nodules \\>4 mm and candidate to additional computed tomography (CT)\n* Signed informed consent\n\nExclusion Criteria:\n\n\\- None\n\nPrevious high-risk negative screening subjects\n\nInclusion Criteria:\n\n* Subjects enrolled in previous lung cancer screening in this Institute with negative computed tomography (CT)\n* Signed informed consent\n\nExclusion Criteria:\n\n\\- None\n\nLung Cancer patients\n\nInclusion Criteria:\n\n* Patients with diagnosis or suspicious diagnosis of lung cancer candidate to surgical treatment or already submitted to it\n* Patients with diagnosis of lung cancer treated with surgical resection\n* Signed informed consent\n\nExclusion Criteria:\n\n* computed tomography (CT) scans not available at San Raffaele Hospital\n* Previous neoadjuvant treatment","18 Years",{"count":50,"type":21},2840,[24],"The study is an interventional pilot study. The study is designed to be monocentric and it presents additional procedues.",[27,54],"Artificial Intelligence (AI)",[56,57,58,59],"CT scan low-dose","Artificial Intelligence","High-risk sucjects","Lung cancer","2024-10-01",{"date":62,"type":32},"2024-10-03",{"date":60,"type":32},{"date":65,"type":21},"2028-11-01",{"name":67,"class":38},"Scientific Institute San Raffaele"]